Journal of the European Academy of Dermatology and Venereology

Volume 28, Issue 9 pp. 1150-1157

Original Article

Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease

T. Bounfour,

T. Bounfour

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

J.-D. Bouaziz,

Corresponding Author

J.-D. Bouaziz

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Conflicts of interest

No conflict of interest.Correspondence: J.-D. Bouaziz. E-mail: [email protected]Search for more papers by this author

M. Bézier,

M. Bézier

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

F. Cordoliani,

F. Cordoliani

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

A. Saussine,

A. Saussine

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

A. Petit,

A. Petit

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

C. Juillard,

C. Juillard

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

M. Bagot,

M. Bagot

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

M. Rybojad,

M. Rybojad

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

T. Bounfour,

T. Bounfour

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

J.-D. Bouaziz,

Corresponding Author

J.-D. Bouaziz

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Conflicts of interest

No conflict of interest.Correspondence: J.-D. Bouaziz. E-mail: [email protected]Search for more papers by this author

M. Bézier,

M. Bézier

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

F. Cordoliani,

F. Cordoliani

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

A. Saussine,

A. Saussine

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

A. Petit,

A. Petit

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

C. Juillard,

C. Juillard

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

M. Bagot,

M. Bagot

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

M. Rybojad,

M. Rybojad

Université Paris Diderot, Sorbonne Paris Cité; AP-HP; Service de Dermatologie, Hôpital Saint Louis, Paris, France

Search for more papers by this author

First published: 01 August 2013

https://doi.org/10.1111/jdv.12223

Citations: 30

Funding sources

None declared.

Share a link

Email
Wechat
Bluesky

Abstract

Background

Treating dermatomyositis (DM) with isolated skin involvement is difficult and inconsistently performed. Intravenous immunoglobulins (IVIg) are recommended for corticoresistant or corticodependant DM, but only a few cases of IVIg use in DM with isolated skin involvement have been reported.

Design

We performed a retrospective monocentric study of 27 patients who were treated with IVIg for severe DM skin lesions (no or minor muscle involvement) after failure of photoprotection and at least one line of treatment.

Results

Nineteen patients (70%) exhibited a major response, four patients exhibited a partial response and four patients exhibited no response, including two patients with grade 3 side effects (headaches). The mean number of IVIg courses was 4.8 (range 1–15). Ten patients (53%) relapsed, with a median time of 6.2 months after the last IVIg course. Six of these patients were successfully treated with a new IVIg course. Muscle disease developed in six patients.

Conclusion

IVIg may be an effective and safe treatment for DM with isolated skin involvement. Relapse occurred frequently, but treatment with a new course of IVIg was successful. Controlled studies are required to confirm these results.

References

1Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344–347.
10.1056/NEJM197502132920706
CAS PubMed Web of Science® Google Scholar
2Rockerbie NR, Woo TY, Callen JP, Giustina T. Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 1989; 20: 629–632.
10.1016/S0190-9622(89)70074-8
PubMed Web of Science® Google Scholar
3Pearson CM. Polymyositis and dermatomyositis. In DJ McCarty, ed. Arthritis and Allied Conditions: A Textbook of Rheumatology, 9th edn. Lea & Febiger, Philadelphia, PA, 1979: 742.
Google Scholar
4Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol 1993; 100: 124S–127S.
10.1038/jid.1993.35
CAS PubMed Web of Science® Google Scholar
5Cherin P, Herson S, Wechsler B, et al. Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet 1990; 336: 116.
10.1016/0140-6736(90)91630-S
PubMed Web of Science® Google Scholar
6Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162–168.
10.1016/0002-9343(91)90009-M
CAS PubMed Web of Science® Google Scholar
7Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169–172.
10.1016/0002-9343(91)90010-U
PubMed Web of Science® Google Scholar
8Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993–2000.
10.1056/NEJM199312303292704
CAS PubMed Web of Science® Google Scholar
9Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994; 21: 1092–1097.
CAS PubMed Web of Science® Google Scholar
10Göttfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 2000; 10: 29–35.
CAS PubMed Web of Science® Google Scholar
11Castanet J, Lacour JP, Ortonne JP. Severe and resistant cutaneous involvement in dermatomyositis: value of intravenous immunoglobulins. Rev Med Interne 1993; 14: 737.
10.1016/S0248-8663(05)81241-X
CAS PubMed Web of Science® Google Scholar
12Kikuchi-Numagami K, Sato M, Tagami H. Successful treatment of a therapy-resistant severely pruritic skin eruption of malignancy-associated dermatomyositis with high-dose intravenous immunoglobulin. J Dermatol 1996; 23: 340–343.
10.1111/j.1346-8138.1996.tb04027.x
CAS PubMed Google Scholar
13Peake MF, Perkins P, Elston DM, Older SA, Vinson RP. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Cutis 1998; 62: 89–93.
CAS PubMed Web of Science® Google Scholar
14Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol 1999; 26: 457–459.
10.1111/j.1346-8138.1999.tb02026.x
CAS PubMed Google Scholar
15Kuwano Y, Ihn H, Yazawa N, et al. Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin. Acta Derm Venereol 2006; 86: 158–159.
PubMed Web of Science® Google Scholar
16Aslanidis S, Pyrpasopoulou A, Kartali N, Zamboulis C. Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis. Clin Rheumatol 2007; 26: 1198–1200.
10.1007/s10067-006-0337-8
PubMed Web of Science® Google Scholar
17Amano H, Nagai Y, Katada K, Hashimoto C, Ishikawa O. Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin. Br J Dermatol 2007; 156: 1390–1392.
10.1111/j.1365-2133.2007.07891.x
CAS PubMed Web of Science® Google Scholar
18Peñate Y, Guillermo N, Melwani P, Martel R, Hernández-Machín B, Borrego L. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol 2009; 60: 1076–1077.
10.1016/j.jaad.2008.09.051
PubMed Web of Science® Google Scholar
19Enk A. European Dermatology Forum Guideline Subcommittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009; 19: 90–98.
PubMed Web of Science® Google Scholar
20Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011; 7: 664–675.
10.1038/nrrheum.2011.139
CAS PubMed Web of Science® Google Scholar
21Cosnes A, Amaudric F, Gherardi R, et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 1995; 131: 1381–1385.
10.1001/archderm.1995.01690240035006
CAS PubMed Web of Science® Google Scholar
22Ueda M, Makinodan R, Matsumura M, Ichihashi M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol 2003; 148: 595–596.
10.1046/j.1365-2133.2003.05209_4.x
CAS PubMed Web of Science® Google Scholar
23Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004; 15: 35–39.
10.1080/09546630310018509
CAS PubMed Google Scholar
24Lampropoulos CE. D' Cruz DP. Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis 2005; 64: 1376–1377.
10.1136/ard.2004.032714
CAS PubMed Web of Science® Google Scholar
25Peyrot I, Sparsa A, Loustaud-Ratti V, et al. Topical tacrolimus and resistant skin lesions of dermatomyositis. Rev Med Interne 2006; 27: 730–735.
10.1016/j.revmed.2006.06.015
CAS PubMed Web of Science® Google Scholar
26James WD, Dawson N, Rodman OG. The treatment of dermatomyositis with hydroxchloroquine. J Rheumatol 1985; 12: 1214–1216.
PubMed Web of Science® Google Scholar
27Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984; 10: 592–600.
10.1016/S0190-9622(84)80263-7
CAS PubMed Web of Science® Google Scholar
28Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005; 141: 855–859.
10.1001/archderm.141.7.855
CAS PubMed Web of Science® Google Scholar
29García-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology (Basel) 2004; 209: 247–248.
10.1159/000079903
CAS PubMed Web of Science® Google Scholar
30Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 1995; 32: 754–757.
10.1016/0190-9622(95)91455-2
CAS PubMed Web of Science® Google Scholar
31Hornung T, Ko A, Tüting T, Bieber T, Wenzel J. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol 2012; 37: 139–142.
10.1111/j.1365-2230.2011.04188.x
CAS PubMed Web of Science® Google Scholar
32Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 1997; 36: 67–71.
10.1016/S0190-9622(97)70327-X
CAS PubMed Web of Science® Google Scholar
33Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367: 2015–2025.
10.1056/NEJMra1009433
CAS PubMed Web of Science® Google Scholar
34Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011; 7: 349–359.
10.1038/nrrheum.2011.61
CAS PubMed Web of Science® Google Scholar
35Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46: 467–474.
10.1002/art.10053
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume28, Issue9

September 2014

Pages 1150-1157

Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease

Conflicts of interest

Conflicts of interest

Funding sources

Abstract

Background

Design

Results

Conclusion

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease

Conflicts of interest

Conflicts of interest

Funding sources

Abstract

Background

Design

Results

Conclusion

References

Citing Literature

References

Related

Information